Evidence map›Paper›PMID 42238435›Full record

ArticlemedRxiv : the preprint server for health sciences2026

Preferences for treatment for latent tuberculosis infection in primary care among people in the United States at increased risk of tuberculosis: a pilot survey.

Hélène E Aschmann, Amy S Tang, Meagan Lee, Katya L Salcedo, Matthew T Murrill, Gina Chen, Yuqian Ouyang, Kit Lui, Mehabuba Rahman, Jennifer Flood and 4 more

Abstract readPreprint
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Hélène E AschmannDivision of Pulmonary and Critical Care Medicine, Zuckerberg San Francisco General Hospital and Trauma Center, University of California San Francisco.ORCID 0000-0003-1234-4321
Amy S TangNorth East Medical Services, San Francisco.ORCID 0000-0002-8151-2686
Meagan LeeNorth East Medical Services, San Francisco.
Katya L SalcedoInstitute for Global Health Sciences, University of California San Francisco.ORCID 0009-0007-5532-8205
Matthew T MurrillCenter for Tuberculosis, University of California San Francisco.ORCID 0000-0001-7567-7727
Gina ChenNorth East Medical Services, San Francisco.
Yuqian OuyangNorth East Medical Services, San Francisco.
Kit LuiNorth East Medical Services, San Francisco.
Mehabuba RahmanDivision of Tuberculosis Elimination, Centers for Disease Control and Prevention, Atlanta, GA, USA.ORCID 0000-0002-7783-1289
Jennifer FloodTuberculosis Control Branch, California Department of Public Health, Richmond, CA, USA.
Andrew D KerkhoffCenter for Tuberculosis, University of California San Francisco.ORCID 0000-0002-5023-6658
Tracy K LinDepartment of Social and Behavioral Sciences, Institute for Health & Aging, University of California San Francisco.ORCID 0000-0002-6528-4564
Priya B SheteDivision of Pulmonary and Critical Care Medicine, Zuckerberg San Francisco General Hospital and Trauma Center, University of California San Francisco.ORCID 0000-0002-0279-8170
Tuberculosis Epidemiologic Studies Consortium

Funding

UCSF-UCB Tuberculosis Research Advancement Center (TRAC)P30AI168440 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI JEFFERY S COX, PAYAM NAHID · 2022 to 2026
$5.8M
Tuberculosis Research and Mentorship Program (TB RAMP II)R25AI147375 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Elizabeth Fair, PAYAM NAHID · 2020 to 2026
$2.8M
NIAID NIH HHS P30 AI168440NIAID NIH HHS R25 AI147375
6 · The paper itself

Abstract

Objectives: Tuberculosis (TB) in the United States disproportionately affects non-U.S.-born individuals. While testing this population for TB infection is recommended, little is known about individuals' willingness to take treatment for latent TB infection (LTBI). To address this gap, we conducted a pilot preference survey among individuals from countries with high TB incidence. Design: Cross-sectional survey supported by language concordant community health workers. Setting: Federally qualified health center, serving a primarily Asian immigrant community, in San Francisco. Participants: Adults eligible for risk-based LTBI testing based on place of birth seeking primary care. Outcome measures: Perspectives on TB disease, risk of reinfection, and willingness to accept treatment if diagnosed with LTBI conditional on different factors, such as side effects, costs, and other treatment burden. Results: Among 60 participants, the median age was 48 years (interquartile range 35-63 years), 52% were women, and 100% spoke Chinese. Infecting others (n=35, 58%), risk of death (n=30, 50%), and potential isolation (n=25, 42%) were the most worrisome consequences of TB disease. Reinfection risk, risk of liver damage, cost, TB progression risk, clinic visits, and blood draws were most often considered moderately or very important when deciding whether to take LTBI treatment (n=53 to 57, 88-95%). While most participants (n=56, 93%) were willing to take treatment if diagnosed with LTBI even at a 10-year TB progression risk below 1% and willing to accept a risk of liver damage (n=41, 68%), less than half would accept LTBI treatment if there were any associated cost (n=28, 47%). Finally, many participants had concerns about their reinfection risk after completing LTBI treatment (n=34, 57%). Conclusions: Amongst surveyed participants, TB disease and its consequences such as hospitalization, death and infecting others were worrisome, and participants had a high level of willingness to take treatment if diagnosed with LTBI. Future assessments of how people weigh tradeoffs regarding LTBI diagnosis and treatment could inform interventions to increase LTBI treatment acceptance and completion.

Identifiers

PMID42238435
PMCPMC13228680

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.